{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:19:23Z","timestamp":1783678763385,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Suzhou Industrial Park Clinical Medical Expert Team Introduction Project","award":["0202140004"],"award-info":[{"award-number":["0202140004"]}]},{"name":"Suzhou Industrial Park Healthcare Talent Support Initiative","award":["202412"],"award-info":[{"award-number":["202412"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05257-3","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:10:40Z","timestamp":1783678240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-cell analysis reveals the molecular regulatory mechanisms of high mobility group box 1 in prostate cancer development and progression"],"prefix":"10.1007","author":[{"given":"Haojie","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"5257_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMe2300807","volume":"388","author":"O Sartor","year":"2023","unstructured":"Sartor O (2023) Localized prostate cancer\u2014then and now. N Engl J Med 388:1617\u20131618. https:\/\/doi.org\/10.1056\/NEJMe2300807","journal-title":"N Engl J Med"},{"key":"5257_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5257_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","volume":"6","author":"R Ge","year":"2022","unstructured":"Ge R, Wang Z, Cheng L (2022) Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis Oncol 6:31. https:\/\/doi.org\/10.1038\/s41698-022-00272-w","journal-title":"NPJ Precis Oncol"},{"key":"5257_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of advanced prostate cancer. Annu Rev Med 70:479\u2013499. https:\/\/doi.org\/10.1146\/annurev-med-051517-011947","journal-title":"Annu Rev Med"},{"key":"5257_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14656566.2022.2033210","volume":"23","author":"EM Yu","year":"2022","unstructured":"Yu EM, Aragon-Ching JB (2022) Advances with androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 23:1015\u20131033. https:\/\/doi.org\/10.1080\/14656566.2022.2033210","journal-title":"Expert Opin Pharmacother"},{"key":"5257_CR6","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s00259-024-06684-z","volume":"51","author":"Y Li","year":"2024","unstructured":"Li Y, Wang S, Zhao S, Zhao P, Huang S, Li K, Han S, Tian C, Li X, Shi B, Li X (2024) Initial [18F]DCFPyL PET\/CT in treatment-na\u00efve prostate cancer: correlation with post-ADT PSA outcomes and recurrence. Eur J Nucl Med Mol Imaging 51:2458\u20132466. https:\/\/doi.org\/10.1007\/s00259-024-06684-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5257_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang S, Zhang Y (2020) HMGB1 in inflammation and cancer. J Hematol Oncol 13:116. https:\/\/doi.org\/10.1186\/s13045-020-00950-x","journal-title":"J Hematol Oncol"},{"key":"5257_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","volume":"23","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R, Zeh HJ, Lotze MT (2023) The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol 23:824\u2013841. https:\/\/doi.org\/10.1038\/s41577-023-00894-6","journal-title":"Nat Rev Immunol"},{"key":"5257_CR9","doi-asserted-by":"publisher","first-page":"172487","DOI":"10.1016\/j.ejphar.2019.172487","volume":"858","author":"YN Paudel","year":"2019","unstructured":"Paudel YN, Angelopoulou E, Piperi C, Balasubramaniam V, Othman I, Shaikh MF (2019) Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: updates on receptor signalling. Eur J Pharmacol 858:172487. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172487","journal-title":"Eur J Pharmacol"},{"key":"5257_CR10","doi-asserted-by":"publisher","first-page":"1384109","DOI":"10.3389\/fonc.2024.1384109","volume":"14","author":"G Lv","year":"2024","unstructured":"Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B, Li X (2024) Multiple functions of HMGB1 in cancer. Front Oncol 14:1384109. https:\/\/doi.org\/10.3389\/fonc.2024.1384109","journal-title":"Front Oncol"},{"key":"5257_CR11","doi-asserted-by":"publisher","first-page":"216494","DOI":"10.1016\/j.canlet.2023.216494","volume":"581","author":"R Chen","year":"2024","unstructured":"Chen R, Zou J, Zhong X, Li J, Kang R, Tang D (2024) HMGB1 in the interplay between autophagy and apoptosis in cancer. Cancer Lett 581:216494. https:\/\/doi.org\/10.1016\/j.canlet.2023.216494","journal-title":"Cancer Lett"},{"key":"5257_CR12","doi-asserted-by":"publisher","first-page":"110904","DOI":"10.1016\/j.cellsig.2023.110904","volume":"112","author":"S Idoudi","year":"2023","unstructured":"Idoudi S, Bedhiafi T, Pedersen S, Elahtem M, Alremawi I, Akhtar S, Dermime S, Merhi M, Uddin S (2023) Role of HMGB1 and its associated signaling pathways in human malignancies. Cell Signal 112:110904. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110904","journal-title":"Cell Signal"},{"key":"5257_CR13","doi-asserted-by":"publisher","first-page":"4487435","DOI":"10.1155\/2022\/4487435","volume":"2022","author":"C Su","year":"2022","unstructured":"Su C, Jia S, Ma Z, Zhang H, Wei L, Liu H (2022) HMGB1 promotes lymphangiogenesis through the activation of RAGE on M2 macrophages in laryngeal squamous cell carcinoma. Dis Markers 2022:4487435. https:\/\/doi.org\/10.1155\/2022\/4487435","journal-title":"Dis Markers"},{"key":"5257_CR14","doi-asserted-by":"publisher","first-page":"e2305724","DOI":"10.1002\/advs.202305724","volume":"11","author":"X Bian","year":"2024","unstructured":"Bian X, Wang W, Abudurexiti M, Zhang X, Ma W, Shi G, Du L, Xu M, Wang X, Tan C, Sun H, He X, Zhang C, Zhu Y, Zhang M, Ye D, Wang J (2024) Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv Sci (Weinh) 11:e2305724. https:\/\/doi.org\/10.1002\/advs.202305724","journal-title":"Adv Sci (Weinh)"},{"key":"5257_CR15","doi-asserted-by":"publisher","first-page":"122270","DOI":"10.1016\/j.lfs.2023.122270","volume":"336","author":"S Khan","year":"2024","unstructured":"Khan S, Baligar P, Tandon C, Nayyar J, Tandon S (2024) Molecular heterogeneity in prostate cancer and the role of targeted therapy. Life Sci 336:122270. https:\/\/doi.org\/10.1016\/j.lfs.2023.122270","journal-title":"Life Sci"},{"key":"5257_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, Dong K, Mariscal J, Liu Y, Soares F, Loo Yau H, Zhang B, Chen W, Wang C, Chen D, Guo Q, Yi Z, Liu M, Fraser M, De Carvalho DD, Boutros PC, Di Vizio D, Jiang Z, van der Kwast T, Berlin A, Wu S, Wang J, He HH, Ren S (2021) Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol 23:87\u201398. https:\/\/doi.org\/10.1038\/s41556-020-00613-6","journal-title":"Nat Cell Biol"},{"key":"5257_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41467-021-27322-4","volume":"13","author":"H Song","year":"2022","unstructured":"Song H, Weinstein HNW, Allegakoen P, Wadsworth MH 2nd, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW (2022) Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun 13:141. https:\/\/doi.org\/10.1038\/s41467-021-27322-4","journal-title":"Nat Commun"},{"key":"5257_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.17305\/bb.2023.9760","volume":"24","author":"Z Tian","year":"2024","unstructured":"Tian Z, Zhu L, Xie Y, Hu H, Ren Q, Liu J, Wang Q (2024) The mechanism of high mobility group box-1 protein and its bidirectional regulation in tumors. Biomol Biomed 24:477\u2013485. https:\/\/doi.org\/10.17305\/bb.2023.9760","journal-title":"Biomol Biomed"},{"key":"5257_CR19","doi-asserted-by":"publisher","first-page":"e13327","DOI":"10.1111\/cpr.13327","volume":"55","author":"C Song","year":"2022","unstructured":"Song C, Pan S, Zhang J, Li N, Geng Q (2022) Mitophagy: a novel perspective for insighting into cancer and cancer treatment. Cell Prolif 55:e13327. https:\/\/doi.org\/10.1111\/cpr.13327","journal-title":"Cell Prolif"},{"key":"5257_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-21-1948","volume":"9","author":"L Zhu","year":"2021","unstructured":"Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, Fang Q, Yu J, Chen P, Wu S, Zheng Z, He Y (2021) A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med 9:1351. https:\/\/doi.org\/10.21037\/atm-21-1948","journal-title":"Ann Transl Med"},{"key":"5257_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","volume":"82","author":"DG Tang","year":"2022","unstructured":"Tang DG (2022) Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin Cancer Biol 82:68\u201393. https:\/\/doi.org\/10.1016\/j.semcancer.2021.11.001","journal-title":"Semin Cancer Biol"},{"key":"5257_CR22","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX (2022) Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci 18:3019\u20133033. https:\/\/doi.org\/10.7150\/ijbs.72534","journal-title":"Int J Biol Sci"},{"key":"5257_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12894-022-00991-z","volume":"22","author":"X Wang","year":"2022","unstructured":"Wang X, Yu J, Yan J, Peng K, Zhou H (2022) Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy. BMC Urol 22:37. https:\/\/doi.org\/10.1186\/s12894-022-00991-z","journal-title":"BMC Urol"},{"key":"5257_CR24","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.xcrm.2022.100604","volume":"3","author":"L De Vargas Roditi","year":"2022","unstructured":"De Vargas Roditi L, Jacobs A, Rueschoff JH, Bankhead P, Chevrier S, Jackson HW, Hermanns T, Fankhauser CD, Poyet C, Chun F, Rupp NJ, Tschaebunin A, Bodenmiller B, Wild PJ (2022) Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Rep Med 3:100604. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100604","journal-title":"Cell Rep Med"},{"key":"5257_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-021-01874-1","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, Guo C, Tang Y, Zhou Y, Liao Q, Wu X, Wang H, Yu J, Li Y, Li X, Li G, Zeng Z, Tan Y, Xiong W (2021) Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res 40:81. https:\/\/doi.org\/10.1186\/s13046-021-01874-1","journal-title":"J Exp Clin Cancer Res"},{"key":"5257_CR26","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1186\/s12885-024-12926-y","volume":"24","author":"X Li","year":"2024","unstructured":"Li X, Li Y, Zhang L, Long H (2024) Single-cell sequencing analysis revealed that NEAT1 was a potential biomarker and therapeutic target of prostate cancer. BMC Cancer 24:1242. https:\/\/doi.org\/10.1186\/s12885-024-12926-y","journal-title":"BMC Cancer"},{"key":"5257_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","volume":"54","author":"R Chen","year":"2022","unstructured":"Chen R, Kang R, Tang D (2022) The mechanism of HMGB1 secretion and release. Exp Mol Med 54:91\u2013102. https:\/\/doi.org\/10.1038\/s12276-022-00736-w","journal-title":"Exp Mol Med"},{"key":"5257_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.31083\/j.fbl2810260","volume":"28","author":"J Wen","year":"2023","unstructured":"Wen J, Zhang X (2023) HMGB1 signaling-mediated tumor immunity in cancer progress. Front Biosci (Landmark Ed) 28:260. https:\/\/doi.org\/10.31083\/j.fbl2810260","journal-title":"Front Biosci (Landmark Ed)"},{"key":"5257_CR29","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.7150\/thno.84388","volume":"13","author":"W Feng","year":"2023","unstructured":"Feng W, Chen J, Huang W, Wang G, Chen X, Duan L, Yin Y, Chen X, Zhang B, Sun M, Luo X, Nie Y, Fan D, Wu K, Xia L (2023) HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2. Theranostics 13:4042\u20134058. https:\/\/doi.org\/10.7150\/thno.84388","journal-title":"Theranostics"},{"key":"5257_CR30","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1158\/1078-0432.Ccr-13-0495","volume":"19","author":"R Kang","year":"2013","unstructured":"Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D (2013) HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19:4046\u20134057. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0495","journal-title":"Clin Cancer Res"},{"key":"5257_CR31","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.7150\/ijbs.73504","volume":"18","author":"H Dong","year":"2022","unstructured":"Dong H, Zhang L, Liu S (2022) Targeting HMGB1: an available therapeutic strategy for breast cancer therapy. Int J Biol Sci 18:3421\u20133434. https:\/\/doi.org\/10.7150\/ijbs.73504","journal-title":"Int J Biol Sci"},{"key":"5257_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3892\/ijo.2018.4420","volume":"53","author":"J Zhang","year":"2018","unstructured":"Zhang J, Shao S, Han D, Xu Y, Jiao D, Wu J, Yang F, Ge Y, Shi S, Li Y, Wen W, Qin W (2018) High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE\/NF-\u03baB signaling pathway. Int J Oncol 53:659\u2013671. https:\/\/doi.org\/10.3892\/ijo.2018.4420","journal-title":"Int J Oncol"},{"key":"5257_CR33","doi-asserted-by":"publisher","first-page":"11933","DOI":"10.1007\/s11033-022-07989-8","volume":"49","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zou N, Deng W, Song C, Yan K, Shen W, Zhu S (2022) HMGB1 induces radioresistance through PI3K\/AKT\/ATM pathway in esophageal squamous cell carcinoma. Mol Biol Rep 49:11933\u201311945. https:\/\/doi.org\/10.1007\/s11033-022-07989-8","journal-title":"Mol Biol Rep"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05257-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05257-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:10:41Z","timestamp":1783678241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05257-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":33,"alternative-id":["5257"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05257-3","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}